Akeso, Inc. Receives Marketing Approval for Ebdarokimab, a New Treatment for Moderate-to-Severe Plaque Psoriasis
"This is fantastic news for psoriasis patients! Finally, a promising new treatment!"
"How does ebdarokimab compare to existing psoriasis treatments?"
"I'm skeptical about the long-term safety profile. Need more data!"
"Is this treatment available worldwide or just in China?"
"Great to see advancements in autoimmune disease treatments!"
"Only four doses a year? Thats a game changer for compliance!"
"Cant wait to see how this impacts patient lives! #Breakthrough"
"Will there be any availability issues with this new drug?"
"Hope this leads to more innovations in autoimmune treatments!"
"Whats next for Akeso after this approval? Exciting times ahead!"
2025-04-18T11:39:00.000Z
Isabelle Moreau
Source of the news: www.prnewswire.com